Braxia Scientific Corp. has completed its training programme for psilocybin-assisted clinical therapy with its first multi-disciplinary cohort of 20 qualified therapists from psychiatry and psychotherapy backgrounds.
Implemented by the Braxia Institute, the training centre is focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy. The programme allows Braxia to develop, train and support qualified, independent medical physicians, psychologists and psychotherapists skilled in best practices to implement safe and effective psilocybin-assisted therapy for patients with depression.
Braxia says it is now ready to start its Health Canada approved psilocybin clinical trial evaluating the safety and efficacy of psilocybin in depression.
CEO, Dr Roger McIntyre, commented: “Braxia Scientific would like to extend congratulations to this pioneering group graduating our training programme.
“Psilocybin-assisted therapy is a rapidly growing and evolving area of interest for medical professionals, clinicians and patients with multiple mental health conditions, including treatment-resistant depression.
“Combining the effects of psilocybin with the support of psychotherapy from a qualified and trusted therapist allows a patient to process the psilocybin experience with the therapist, providing the basis for a better treatment outcome.”
All enrolled therapists were required to complete a practicum component, in which they gained experience in administering psilocybin-assisted therapy for participants with depression as part of the upcoming clinical trial. Braxia said it anticipates that, pending regulatory approval of psilocybin, therapists would also be trained to implement psychedelics in clinical practice.
“As mental health professionals, we continually strive to deliver innovative treatment options that will result in better outcomes in persons affected by depression and related disorders,” said McIntyre.
“We are encouraged to see the growing number of clinical studies focused on demonstrating that psilocybin, and potentially other psychedelics, may be safe and effective in treating people with mental health conditions, and we are focused on providing healthcare professionals with the training, competencies and practical experience to address the need for safe, legal and affordable access to high-quality psilocybin-assisted therapy as regulatory approval is sought for these innovative treatments.”
